Acute cutaneous lupus erythematosus

Cutaneous Lupus Erythematosus Market Insight & Forecast Reveals USD 1.2 Billion Growth Potential by 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
General Health, Pharmaceutical, Health, Other Health, EU4, DLE, Histology, Education, LET, Classification, Biogen, Epidemiology, Lupus, Bristol Myers Squibb, Acute cutaneous lupus erythematosus, Cancer, Research, SLE, Risk, USD, CLE, Diagnosis, Deucravacitinib, Horizon Therapeutics, Systemic disease, Nature, Immunoglobulin G, TYK2, LEP, LE, BDCA2, Vaccine, Medical device, Pharmaceutical industry, Medical imaging, Skin

The "Cutaneous Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cutaneous Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the Cutaneous Lupus Erythematosus market in the 7MM and China was approximately USD 580 million, expected to reach USD 1.2 billion by 2032.
  • Notably, Biogen's litifilimab and Bristol Myers Squibb's deucravacitinib will lead the Cutaneous Lupus Erythematosus market in the forecast period.
  • In 2022, the total market size of Cutaneous lupus erythematosus in the 7MM and China was ~USD 580 million, expected to reach ~USD 1,260 million by 2032.

Lupus Research Alliance Announces Four New Recipients of the Lupus Mechanisms and Targets Award

Retrieved on: 
Thursday, April 20, 2023
Lupus Research Alliance, Therapy, Urine, LRA, Acute kidney injury, Skin, SLE, Lupus, Inflammation, SGLT2, Fibrosis, Acute cutaneous lupus erythematosus, CD8, Patient, Risk, Blood, Lupus nephritis, IRF5, Mouse, CXCR6, CXCL16, Interferon, STK25, LMTA, Pharmaceutical industry, Vaccine

NEW YORK, April 20, 2023 /PRNewswire/ -- The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing or reducing lupus disease activity. Lupus has a broad range of causes and symptoms, and these multiple approaches are important for designing customized therapies that can provide better outcomes for a wide range of patients.

Key Points: 
  • NEW YORK, April 20, 2023 /PRNewswire/ -- The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients.
  • The winning four projects collectively test potential treatment approaches to prevent lupus from developing or reducing lupus disease activity.
  • "These four new LMTA awards support innovative lupus researchers whose work is poised to deliver much needed new information for the lupus field.
  • She will also investigate if targeting these two molecules will provide a lasting treatment response in pet dogs with skin lupus through a veterinary clinical trial.

Ventus Therapeutics to Present Data on Novel cGAS Small Molecule Inhibitors in the Modulation of Auto-Inflammation

Retrieved on: 
Wednesday, November 3, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Infection, UVB, Neurology, National Center for Advancing Translational Sciences, Biotechnology, Acute cutaneous lupus erythematosus, LinkedIn, Nucleic acid metabolism, Inflammation, Industry, Neurodegeneration, Drug development, Human, Dermatomyositis, Patient, Lupus, Cytokine, Pain scale, NLRP3, Chemokine, Ultraviolet, Protein, Mitochondrial disease, Cytoplasm, Resolve, COVID-19, Computational chemistry, Lists of diseases, American College, Bureau of Oceans and International Environmental and Scientific Affairs, Therapy, Cyclic GMP-AMP synthase, Doctor of Philosophy, Mouse, TREX1, DNA, Fine chemical, Pharmaceutical industry, Vaccine

These presentations will highlight results that describe how Ventus proprietary technology and enablement could drive the design of chemically distinct cGAS-targeted small molecule therapeutics capable of addressing a wide range of indications.

Key Points: 
  • These presentations will highlight results that describe how Ventus proprietary technology and enablement could drive the design of chemically distinct cGAS-targeted small molecule therapeutics capable of addressing a wide range of indications.
  • cGAS has been a challenging target for small molecule drug discovery and to our knowledge there is no cGAS inhibitor in clinical development, said Michael Crackower, PhD, Chief Scientific Officer of Ventus.
  • cGAS is a sensor of double-stranded DNA in the cytoplasm; cytoplasmic DNA can be indicative of infection, mitochondrial disease or nuclear leakage.
  • Ventus Therapeutics is a biopharmaceutical company utilizing cutting-edge computational tools to design small molecule therapeutics across multiple therapeutic areas, including immunology, inflammation and neurology.

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus

Retrieved on: 
Tuesday, June 29, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Cutaneous lupus erythematosus, Autoimmune diseases, Branches of biology, Medicine, Lupus, Plasmacytoid dendritic cell, Dendritic cell, Anifrolumab, Acute cutaneous lupus erythematosus, HZN-7734, Systemic Lupus Erythematosus (SLE), Horizon, HZN-7734, SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), HORIZON

HZN-7734 also improved Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ( CLASI-A ) scores, a clinical measure of cutaneous lupus, versus placebo.

Key Points: 
  • HZN-7734 also improved Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ( CLASI-A ) scores, a clinical measure of cutaneous lupus, versus placebo.
  • The composite primary endpoint of the Phase 2 trial is change in the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) and reduction in oral glucocorticoid dose after 48 weeks.
  • Additional trial endpoints include other measures of both lupus disease activity and oral glucocorticoid reduction.
  • Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in subjects with cutaneous lupus.

Global Systemic Lupus Erythematosus Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Other Health, Autoimmune diseases, Medical specialties, Clinical medicine, Connective tissue diseases, Medicine, Cutaneous lupus erythematosus, Lupus erythematosus, Lupus, Sjögren syndrome, Systemic, Acute cutaneous lupus erythematosus, Lupus Canada

b'The "Global Systemic Lupus Erythematosus Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Systemic Lupus Erythematosus Epidemiology and Patient Flow Analysis - 2021, provides Systemic Lupus Erythematosus epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Systemic Lupus Erythematosus Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Systemic Lupus Erythematosus Epidemiology and Patient Flow Analysis - 2021, provides Systemic Lupus Erythematosus epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Systemic Lupus Erythematosus patients, history of the disease at the population level (Systemic Lupus Erythematosus prevalence, Systemic Lupus Erythematosus incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSystemic Lupus Erythematosus patient flow: Systemic Lupus Erythematosus prevalence, diagnosed, and drug-treated patients\nDemographics: Systemic Lupus Erythematosus patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Systemic Lupus Erythematosus market sizing, assessing market potential, and developing drug forecast models\nIdentify Systemic Lupus Erythematosus patients segments through age groups, gender, and disease sub-types\nEvaluate Systemic Lupus Erythematosus market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005191/en/\n'

PPD and Lupus Therapeutics Collaborate to Support Lupus Clinical Research

Retrieved on: 
Thursday, September 3, 2020
Research, Technology, Medical devices, Clinical trials, Cardiology, Biotechnology, Pharmaceutical, Health, Data management, Science, Medical specialties, Cutaneous lupus erythematosus, Clinical medicine, Medicine, Autoimmune diseases, Lupus, RTT, William Osler, Rheumatology, Acute cutaneous lupus erythematosus, Lupus erythematosus, Alliance for Lupus Research, PPD, Lupus Therapeutics

PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPDs pharmaceutical and biotech customers.

Key Points: 
  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPDs pharmaceutical and biotech customers.
  • With the urgent need for new lupus treatments, we look forward to working with PPD on ways to accelerate and optimize the development of lupus clinical research, said Albert T. Roy, executive director, Lupus Therapeutics.
  • Some of the key indications that Lupus Therapeutics addresses include SLE, lupus nephritis, chronic cutaneous (discoid) lupus, subacute cutaneous lupus, acute cutaneous lupus and central nervous system lupus.
  • Lupus Therapeutics is an affiliate of the Lupus Research Alliance, which aims to transform treatment while advancing toward a cure by financing the most innovative lupus research in the world.